Exhibit 99.1

Letter from Peter T. Kissinger, Ph.D. and Candice B. Kissinger to the
Board of Directors of Bioanalytical Systems, Inc.




                             PETER T. KISSINGER, PH.D. AND CANDICE B. KISSINGER
                                                               111 Lorene Place
                                             West Lafayette, Indiana 47906-8620

April 6, 2009

Board of Directors of Bioanalytical Systems, Inc.
c/o Corporate Secretary, Bioanalytical Systems, Inc.
2701 Kent Avenue
West Lafayette, IN 47906

Dear Sirs:

         As you know, we collectively own 26% of the common stock of
Bioanalytical Systems, Inc. (the "Company"), and are the Company's largest
shareholders. As the founder of the Company and members of the Company's
executive management team until 2007, we have both a personal and a significant
financial stake in the success of the Company. Since our departure from the
active management of the Company, we have grown increasingly concerned
regarding the operations, financial condition and management of the Company.

         Financial Results. For each of the quarters in fiscal 2008 and
continuing in the first quarter of fiscal 2009, the Company has reported net
losses, which continue to increase quarter-over-quarter, including a net loss
of $1.6 million in the first quarter of fiscal 2009. For fiscal 2008, while
revenues increased 4.9% from fiscal 2007, expenses increased at a faster rate,
including a 40.6% increase year-over-year in selling expenses and a 14.1%
increase year-over-year in general and administrative expenses. In the first
quarter of 2009, this trend worsened, as revenues decreased 23.6%, while
selling expenses increased 26.9% and general and administrative expenses
increased 31.4% compared to the first quarter of fiscal 2008. In contrast,
research and development has long been essential to the success of the Company.
During fiscal 2008, expenses for research and development actually decreased
by 11.4% year-over-year and in the first quarter of fiscal 2009, the amount
spent on research and development was only 6% of total operating expenses
for the quarter.

         While the current economic crisis has negatively impacted the Company
and its industry as a whole, we do not believe that this is the sole reason for
the increased net losses recognized by the Company in the most recent fiscal
quarters.

         Stock Price. Since the end of fiscal 2008, the price of the Company's
common stock has declined significantly. On September 30, 2008, the Company's
closing stock price on the NASDAQ Global Market was $4.60. Comparatively, on
April 2, 2009, the Company's closing stock price was $1.25. As stated above, we
do not believe that the current economic situation is the sole reason for this
decline in the Company's stock price. Rather, we believe that investor
confidence has declined, which has impacted the Company's stock price.

         Departure of Key Employees. Over the past several months, several key
members of management and other key employees have left the Company. As stated
in the Annual Report on Form 10-K for fiscal 2008, "In particular, since
September 30, 2008, we experienced substantial turnover in our marketing and
business development teams. Specifically, our Senior Vice President and Chief
Business Officer, our Vice President of Business Development and several of our
leading sales team are no longer with the Company." Emilio Cordova, the former
Vice President of Business Development, had worked for the Company for 12
years. Ronald Shoup, the former Chief Scientific Officer, retired from the
Company in September 2008 after nearly 30 years of service with the Company.
In addition, several other key sales people and scientists have left the
Company in the last few months. These individuals built strong relationships
with many of the Company's customers, and we believe that their departures
have negatively affected the Company's relationships with these customers.



         Executive Compensation Arrangements. As described in the Company's
proxy statement for the annual meeting held on March 19, 2009, Messrs.
Shepperd, Cox, Brewer and Chilton have entered into employment agreements
with the Company. Each of these employment agreements contain "golden
parachute" provisions in the event of a change in control that we believe go
beyond that which would be necessary to retain these individuals if a change
in control occurred. In particular, Mr. Shepperd's agreement originally
provided for a payment upon a change in control, but only if he was
involuntarily terminated within one year following the change in control.
In January 2009, the Company entered into an amendment to his employment
agreement, and now Mr. Shepperd will receive a payment of $201,600 merely upon
the occurrence of a change in control.

         We also are concerned with bonus payments that were awarded to Mr. Cox
in 2007 and 2008. Despite the Company's operating results and material
weaknesses identified by the independent auditors, Mr. Cox received bonus
payments totaling $65,000 in 2007 and 2008. We are not certain how these
bonuses fit with the current focus of shareholders generally on
pay-for-performance at public companies.

         Limited Shareholder Stake by Management. As previously stated,
collectively we own 26% of the Company's common stock. Per the proxy statement
filed in connection with the Company's annual meeting held on March 19, 2009,
the Board of Directors, in the aggregate, only owns 4.1% of the Company's
common stock, 3.0% of which is owned by one director. Mr. Shepperd, President
and Chief Executive Officer of the Company and also a member of the Board,
only owns 0.3% of the Company's common stock, and Mr. Cox, Chief Financial
Officer of the Company, is listed as having no ownership interest in the
Company. As a result, the interests of management and the Board may not be
aligned with those of the Company's shareholders.

         Dissatisfaction of Shareholders. We are clearly not the only
shareholders that are concerned about the current state of the Company. On
April 1, 2009, Thomas Harenburg, beneficial owner of 5.6% of the outstanding
shares of the Company's common stock, filed a Schedule 13D with the Securities
and Exchange Commission, requesting that his director nominee replace one of
the current Board members prior to the next regularly scheduled Board meeting.
Prior to that, at the annual meeting of shareholders held on March 19, 2009,
over 95% of the Company's outstanding shares were voted in person or by proxy.
At that meeting, each of the five director nominees received over 50% withheld
votes, with the average withheld vote being 57%. No director received more
than 50% of the votes "for" his election. Market data shows that it is unusual
for an individual director of a public company to receive such a high
percentage of votes against his or her re-election, let alone the entire slate
of directors.  In fact, many public companies have a majority voting standard
for directors, unlike our plurality voting standard, which means that if a
director does not receive a majority of votes "for" his election (which was
the case for each of the Company's directors), he would be required to resign
from the Board.

         As significant shareholders in the Company, and coupled with the
Company's recent operating results and evident lack of shareholder confidence
in the current directors demonstrated by the votes at the last shareholders'
meeting:

         1. We request that the Independent Directors of the Board meet with us
to discuss the current financial condition and management of the Company,
including the executive compensation arrangements currently in place, Mr.
Shepperd's qualifications and knowledge regarding the Company's industry, and
the feasibility of the Company going private or pursuing other strategic
alternatives.

         2. As stated in the Company's proxy statement for its annual meeting
of shareholders held on March 20, 2008, "Dr. Kissinger has been named Chairman
Emeritus of the Board of Directors, a non-voting, uncompensated position that
provides for his continued input into matters coming before the Board." Since
being appointed Chairman Emeritus, Dr. Kissinger has not been included in
matters coming before the Board and has not received Board materials or minutes
from the meetings held. We therefore request that, commencing with the next
meeting of the Board, the Board honor Dr. Kissinger's position as Chairman
Emeritus by permitting him to attend all Board meetings and by providing him
with all materials provided to Board members in connection with regularly
scheduled Board meetings or otherwise.



         3. Effective immediately, we request that the Company not enter into
any new agreements with severance or change in control arrangements. In
addition, we request that the Company not renew the term of any employment
agreements or permit the automatic renewal or extension of any employment
agreements with any of the Company's officers.

         4. We request that the Board promptly agree to replace three of the
current members of the Board with three directors of our choosing.

If the Board fails to honor these requests, we reserve the right to take any
and all further action.

         We believe that there is significant value in the Company and we look
forward to your cooperation in helping to restore it.

Sincerely,

/s/  Peter T. Kissinger, Ph.D.                /s/  Candice B. Kissinger

Peter T. Kissinger, Ph.D.                     Candice B. Kissinger